Sexcord/ stromal ovarian tumors screening: Difference between revisions
| Line 15: | Line 15: | ||
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3]. | According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3]. | ||
==Screening== | ==Screening== | ||
The US Preventive Services Task Force(USPSTF) recommends against screening for ovarian cancer in asymptomatic women | *The US Preventive Services Task Force(USPSTF) recommends against screening for ovarian cancer in asymptomatic women | ||
*The USPSTF found that screening with either transvaginal ultrasound or testing for the serum tumor marker cancer antigen 125 (CA-125) or a combination of both does not reduce ovarian cancer mortality | |||
==References== | ==References== | ||
Revision as of 23:17, 31 March 2019
|
Sexcord/ stromal ovarian tumors Microchapters |
|
Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Sexcord/ stromal ovarian tumors screening On the Web |
|
American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors screening |
|
Risk calculators and risk factors for Sexcord/ stromal ovarian tumors screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
- The US Preventive Services Task Force(USPSTF) recommends against screening for ovarian cancer in asymptomatic women
- The USPSTF found that screening with either transvaginal ultrasound or testing for the serum tumor marker cancer antigen 125 (CA-125) or a combination of both does not reduce ovarian cancer mortality